AZD-5423 is a nonsteroidal glucocorticoid and phase II experimental drug being developed by AstraZeneca[1] and disclosed at the spring 2013 American Chemical Society meeting in New Orleans to treat respiratory diseases and in particular chronic obstructive pulmonary disease.

[2][3][4][5][6] It has completed a phase II clinical trial.

[7]

This drug article relating to the respiratory system is a stub.

You can help Wikipedia by expanding it.